EP1660464A4 - Inhibiteurs de caspase contenant des cycles isoxazoline - Google Patents

Inhibiteurs de caspase contenant des cycles isoxazoline

Info

Publication number
EP1660464A4
EP1660464A4 EP04774400A EP04774400A EP1660464A4 EP 1660464 A4 EP1660464 A4 EP 1660464A4 EP 04774400 A EP04774400 A EP 04774400A EP 04774400 A EP04774400 A EP 04774400A EP 1660464 A4 EP1660464 A4 EP 1660464A4
Authority
EP
European Patent Office
Prior art keywords
caspase inhibitors
inhibitors containing
isoxazoline ring
containing isoxazoline
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP04774400A
Other languages
German (de)
English (en)
Other versions
EP1660464B1 (fr
EP1660464A1 (fr
Inventor
Hye-Kyung Chang
Yeong-Soo Oh
Cheol-Won Park
Yong-Jin Jang
Tae-Kyo Park
Sung-Sub Kim
Min-Jung Kim
Mi-Jeong Park
Jung-Gyu Park
Hee-Dong Park
Kyeong-Sik Min
Tae-Soo Lee
Sang-Kyun Lee
Soo-Hyeon Kim
Hee-Kyung Jeong
Sun-Hwa Lee
Hwa-Dong Kim
Ae-Ri Kim
Ki-Sook Park
Hyun-Ik Shin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Chem Ltd
Original Assignee
LG Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LG Life Sciences Ltd filed Critical LG Life Sciences Ltd
Publication of EP1660464A1 publication Critical patent/EP1660464A1/fr
Publication of EP1660464A4 publication Critical patent/EP1660464A4/fr
Application granted granted Critical
Publication of EP1660464B1 publication Critical patent/EP1660464B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EP04774400.8A 2003-08-27 2004-08-26 Inhibiteurs de caspase contenant des cycles isoxazoline Expired - Lifetime EP1660464B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20030059451 2003-08-27
PCT/KR2004/002139 WO2005021516A1 (fr) 2003-08-27 2004-08-26 Inhibiteurs de caspases contenant un cycle isoxazolinique

Publications (3)

Publication Number Publication Date
EP1660464A1 EP1660464A1 (fr) 2006-05-31
EP1660464A4 true EP1660464A4 (fr) 2008-11-26
EP1660464B1 EP1660464B1 (fr) 2015-02-25

Family

ID=36102769

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04774400.8A Expired - Lifetime EP1660464B1 (fr) 2003-08-27 2004-08-26 Inhibiteurs de caspase contenant des cycles isoxazoline

Country Status (26)

Country Link
US (1) US7557133B2 (fr)
EP (1) EP1660464B1 (fr)
JP (1) JP4503017B2 (fr)
KR (1) KR100594544B1 (fr)
CN (1) CN1842521B (fr)
AP (1) AP2104A (fr)
AR (1) AR045503A1 (fr)
BR (1) BRPI0413848B8 (fr)
CA (1) CA2535711C (fr)
EA (1) EA012080B1 (fr)
EC (1) ECSP066378A (fr)
EG (1) EG25751A (fr)
IL (1) IL173638A (fr)
MA (1) MA27999A1 (fr)
MX (1) MXPA06002267A (fr)
MY (1) MY162110A (fr)
NO (1) NO335620B1 (fr)
NZ (1) NZ545216A (fr)
OA (1) OA13244A (fr)
PE (1) PE20050371A1 (fr)
TR (1) TR200600899T2 (fr)
TW (1) TWI346110B (fr)
UA (1) UA83240C2 (fr)
UY (1) UY28494A1 (fr)
WO (1) WO2005021516A1 (fr)
ZA (1) ZA200601586B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100774999B1 (ko) * 2005-02-26 2007-11-09 주식회사 엘지생명과학 이소옥사졸린 유도체 및 그의 제조 방법
US7754909B1 (en) * 2005-04-06 2010-07-13 The Florida State University Research Foundation, Inc. Compounds and methods of arylmethylation (benzylation) as protection for alcohol groups during chemical synthesis
KR101299720B1 (ko) * 2006-08-16 2013-08-28 주식회사 엘지생명과학 3-아미노-5-플루오로-4-디알콕시펜탄산 에스테르의 새로운제조방법
KR20080042290A (ko) * 2006-11-09 2008-05-15 주식회사 엘지생명과학 피리돈 구조를 포함하는 캐스파제 저해제
CN101778833A (zh) 2007-08-10 2010-07-14 日本曹达株式会社 含氮杂环化合物和有害生物防除剂
KR20090099886A (ko) * 2008-03-18 2009-09-23 주식회사 엘지생명과학 캐스파제 저해제의 프로드럭
US8791235B2 (en) 2008-05-21 2014-07-29 Novagenesis Foundation Selective caspase inhibitors and uses thereof
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EA024512B1 (ru) 2011-03-31 2016-09-30 Байер Интеллектуэль Проперти Гмбх Гербицидно и фунгицидно действующие 3-фенилизоксазолин-5-карбоксамиды и 3-фенилизоксазолин-5-тиоамиды
DK2697246T3 (en) * 2011-04-15 2018-05-28 Genesis Tech Limited SELECTIVE CYSTEIN PROTEASE INHIBITORS AND USES THEREOF
JP6285937B2 (ja) * 2012-09-25 2018-02-28 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 除草性および殺真菌性の５−オキシ置換３−フェニルイソオキサゾリン−５−カルボキサミドおよび５−オキシ置換３−フェニルイソオキサゾリン−５−チオアミド
DK2900645T3 (da) * 2012-09-25 2019-10-14 Bayer Cropscience Ag Herbicidt aktive 3-phenylisoxazolinderivater
EP2900660B1 (fr) 2012-09-25 2018-01-17 Bayer CropScience AG 3-hétéroarylisoxazoline-5-carboxamides et 3-hétéroarylisoxazoline-5-thioamides à action herbicide et fongicide
JP2017095353A (ja) * 2014-03-27 2017-06-01 日本曹達株式会社 イソオキサゾリン−５−カルボキサミド化合物および有害生物防除剤
JP2017515854A (ja) 2014-05-12 2017-06-15 クオナトウス ファーマシューティカルズ，インコーポレイテッド カスパーゼ阻害剤による慢性肝疾患の合併症の治療
CN105753853B (zh) 2014-12-16 2020-08-04 沈阳中化农药化工研发有限公司 一种含异恶唑啉的脲嘧啶类化合物及其用途
WO2017079566A1 (fr) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Inhibiteurs de caspase destinés à être utilisés dans le traitement du cancer
CA3010286A1 (fr) 2015-12-31 2017-07-06 Conatus Pharmaceuticals Inc. Methodes d'utilisation d'inhibiteurs de caspase dans le traitement d'une hepatopathie
RU2019113150A (ru) 2016-10-05 2020-11-06 Новартис Аг Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения
WO2018133870A1 (fr) * 2017-01-23 2018-07-26 正大天晴药业集团股份有限公司 Composé cyclique lié en tant qu'inhibiteur de caspase
US11613522B2 (en) 2017-06-13 2023-03-28 Bayer Aktiengesellschaft Herbicidally active 3-phenylisoxazoline-5-carboxamides of tetrahydro- and dihydrofurancarboxamides
DK3638665T3 (da) 2017-06-13 2021-10-11 Bayer Ag Herbicidt virksomme 3-phenylisoxazolin-5-carboxamider af tetrahydro- og dihydrofurancarboxylsyrer og -estere
JP7198519B2 (ja) 2017-08-17 2023-01-04 バイエル・アクチエンゲゼルシヤフト シクロペンチルカルボン酸類及びエステル類の除草活性３－フェニル－５－トリフルオロメチルイソオキサゾリン－５－カルボキサミド類
CA3089286A1 (fr) 2018-01-25 2019-08-01 Bayer Aktiengesellschaft 3-phenyl-isoxazoline-5-carboxamides de derives d'acide cyclopentenyl-carboxylique a action herbicide
ES2950189T3 (es) 2019-03-12 2023-10-05 Bayer Ag 3-fenilisoxazolina-5-carboxamidas de ésteres de ácido ciclopentenilcarboxílico que contienen s herbicidas
JP2022529973A (ja) * 2019-04-19 2022-06-27 エルジー・ケム・リミテッド カスパーゼ阻害剤のプロドラッグ
KR102442103B1 (ko) * 2019-04-30 2022-09-08 주식회사 엘지화학 캐스파제 저해제의 프로드럭
KR102366226B1 (ko) * 2019-05-31 2022-02-22 주식회사 엘지화학 캐스파제 저해제 프로드럭을 함유하는 주사용 조성물 및 이의 제조 방법
TWI906428B (zh) 2020-12-10 2025-12-01 南韓商Ｌｇ化學股份有限公司 酸（Ｂｏｒｏｎｉｃ Ａｃｉｄ）化合物
WO2022123062A1 (fr) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocage de la caspase et/ou de la fasl pour prévenir une issue fatale chez des patients atteints de la covid-19
CN114908028B (zh) * 2022-04-19 2024-05-31 杭州师范大学 一种双相体系下化学酶法级联催化腈类化合物的一锅法合成工艺
WO2026064271A1 (fr) 2024-09-23 2026-03-26 Fmc Corporation Dérivés amides bicycliques substitués utilisés en tant qu'herbicides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710159A (en) * 1996-05-09 1998-01-20 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2738486B2 (ja) * 1992-11-20 1998-04-08 ファイザー製薬株式会社 抗炎症剤としての新規なイソオキサゾリン類
CN1046274C (zh) * 1993-11-26 1999-11-10 辉瑞大药厂 用作消炎剂的异噁唑啉化合物
JP2818820B2 (ja) * 1993-11-26 1998-10-30 ファイザー・インク． 抗炎症剤としての３−アリール−２−イソオキサゾリン類
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
KR100373375B1 (ko) * 1998-04-03 2003-06-12 주식회사 엘지생명과학 인터루킨-1b-컨버팅효소및아포파인/cpp-32에대한저해제
EP1212309B1 (fr) * 1999-09-17 2004-08-18 LG Chem Investment, Ltd. Inhibiteur de caspases
WO2001021599A1 (fr) * 1999-09-17 2001-03-29 Lg Chemical Ltd. Inhibiteur de caspase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710159A (en) * 1996-05-09 1998-01-20 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists

Also Published As

Publication number Publication date
TR200600899T2 (tr) 2006-09-21
US7557133B2 (en) 2009-07-07
US20060223848A1 (en) 2006-10-05
JP2007503429A (ja) 2007-02-22
OA13244A (en) 2007-01-31
TW200512199A (en) 2005-04-01
NO335620B1 (no) 2015-01-12
UY28494A1 (es) 2005-02-28
KR100594544B1 (ko) 2006-06-30
PE20050371A1 (es) 2005-08-17
BRPI0413848B1 (pt) 2019-04-30
WO2005021516A1 (fr) 2005-03-10
HK1092788A1 (en) 2007-02-16
CN1842521B (zh) 2012-09-05
AP2006003509A0 (en) 2006-02-28
CN1842521A (zh) 2006-10-04
ZA200601586B (en) 2007-05-30
KR20050022364A (ko) 2005-03-07
TWI346110B (en) 2011-08-01
EP1660464B1 (fr) 2015-02-25
NZ545216A (en) 2009-06-26
BRPI0413848B8 (pt) 2021-05-25
AP2104A (en) 2010-02-06
NO20061362L (no) 2006-03-24
CA2535711A1 (fr) 2005-03-10
EA200600465A1 (ru) 2006-08-25
IL173638A (en) 2011-12-29
EA012080B1 (ru) 2009-08-28
JP4503017B2 (ja) 2010-07-14
MXPA06002267A (es) 2006-05-17
ECSP066378A (es) 2006-08-30
AR045503A1 (es) 2005-11-02
CA2535711C (fr) 2011-07-05
UA83240C2 (ru) 2008-06-25
EG25751A (en) 2012-06-25
BRPI0413848A (pt) 2006-10-24
IL173638A0 (en) 2006-07-05
MY162110A (en) 2017-05-31
MA27999A1 (fr) 2006-07-03
EP1660464A1 (fr) 2006-05-31
AU2004268895A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
EG25751A (en) Caspase inhibitors containing isoxazoline ring
AU153882S (en) Ring
GB0315111D0 (en) Substituted 5-membered ring compounds and their use
AU153411S (en) Watchcase
AU152718S (en) Wristwatch
PL2258188T3 (pl) Mieszaniny chwastobójcze zawierające pikolinafen
AU156750S (en) Watch case
EP1704142A4 (fr) Inhibiteurs de la protease
ZA200505418B (en) Cathepsin S inhibitors
AU149626S (en) Ring
EP1622615A4 (fr) Inihbiteurs de l'integrase de la naphtyridine
AU158134S (en) Ring
GB0311195D0 (en) Glyoxalase inhibitors
AU158133S (en) Watch
AU154468S (en) Watch
GB0312619D0 (en) Complement inhibitors
GB2402749B (en) Ring dividing device
AU153832S (en) Ring
AU153829S (en) Ring
HU0300249V0 (en) Ring for penial
GB0329434D0 (en) An improved watch
PL360019A1 (en) Gps
GB0313751D0 (en) Isoxazole compounds
GB0303105D0 (en) Isoxazole compounds
GB0306560D0 (en) Isoxazole compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060216

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1092788

Country of ref document: HK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEE, JAE-HOON,R & D PARK, LG LIFE SCIENCES LTD.

Inventor name: LEE, KYU-WOONG,R & D PARK, LG LIFE SCIENCES LTD.

Inventor name: SHIN, HYUN-IK,R & D PARK, LG LIFE SCIENCES LTD.

Inventor name: PARK, KI-SOOK,R&D PARK, LG LIFE SCIENCES LTD.

Inventor name: PARK, HEE-DONG,R&D PARK, LG LIFE SCIENCES LTD.

Inventor name: SEONG, JEONG HUIR&D PARK, LG LIFE SCIENCES LTD.

Inventor name: KWON, TAE-SIK,R & D PARK, LG LIFE SCIENCE LTD.

Inventor name: KIM, MIN-JUNG,R&D PARK, LG LIFE SCIENCES LTD.

Inventor name: KIM, SOO-HYEON,R&D PARK, LG LIFE SCIENCES LTD.

Inventor name: JEONG, HEE-KYUNG,R&D PARK, LG LIFE SCIENCES LTD.

Inventor name: PARK, CHEOL-WON,R&D PARK, LG LIFE SCIENCES LTD.

Inventor name: KIM, AE-RI,R&D PARK, LG LIFE SCIENCES LTD.

Inventor name: KIM, HWA-DONG,R&D PARK, LG LIFE SCIENCES LTD.

Inventor name: CHOI, HYEONG-WOOK,R&D PARK, LG LIFE SCIENCES LTD.

Inventor name: LEE, SANG-KYUN,R&D PARK, LG LIFE SCIENCES LTD.

Inventor name: KIM, HO-JUN,R & D PARK, LG LIFE SCIENCES LTD.

Inventor name: PARK, TAE-KYO,R&D PARK, LG LIFE SCIENCES LTD.

Inventor name: LEE, SUN-HWA,R&D PARK, LG LIFE SCIENCES LTD.

Inventor name: OH, YEONG-SOO,R&D PARK, LG LIFE SCIENCES LTD.

Inventor name: KIM, SUNG-SUB,R&D PARK, LG LIFE SCIENCES LTD.

Inventor name: PARK, MI-JEONG,R&D PARK, LG LIFE SCIENCES LTD.

Inventor name: HEO, TAE-HO,R & D PARK, LG LIFE SCIENCES LTD.

Inventor name: JANG, YONG-JIN,R&D PARK, LG LIFE SCIENCES LTD.

Inventor name: PARK, JUNG-GYU,R&D PARK, LG LIFE SCIENCES LTD.

Inventor name: MIN, KYEONG-SIK,R&D PARK, LG LIFE SCIENCES LTD.

Inventor name: LEE, TAE-SOO,R&D PARK, LG LIFE SCIENCES LTD.

Inventor name: CHANG, HYE-KYUNG,R&D PARK, LG LIFE SCIENCES LTD.

A4 Supplementary search report drawn up and despatched

Effective date: 20081023

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/42 20060101ALI20081017BHEP

Ipc: C07D 261/04 20060101AFI20050314BHEP

Ipc: A61P 29/00 20060101ALI20081017BHEP

17Q First examination report despatched

Effective date: 20110516

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 413/04 20060101ALN20140730BHEP

Ipc: C07D 413/12 20060101ALN20140730BHEP

Ipc: C07D 413/14 20060101ALN20140730BHEP

Ipc: C07D 261/04 20060101AFI20140730BHEP

INTG Intention to grant announced

Effective date: 20140904

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MICHELI AND CIE SA, CH

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602004046680

Country of ref document: DE

Effective date: 20150409

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 711854

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150415

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20150225

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 711854

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150526

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004046680

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20151126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1092788

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004046680

Country of ref document: DE

Representative=s name: HERNANDEZ, YORCK, DIPL.-ING., DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004046680

Country of ref document: DE

Representative=s name: HOFFMANN EITLE PATENT- UND RECHTSANWAELTE PART, DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20040826

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004046680

Country of ref document: DE

Representative=s name: HERNANDEZ, YORCK, DIPL.-ING., DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004046680

Country of ref document: DE

Owner name: LG CHEM, LTD., KR

Free format text: FORMER OWNER: LG LIFE SCIENCES LTD., SEOUL/SOUL, KR

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004046680

Country of ref document: DE

Representative=s name: HOFFMANN EITLE PATENT- UND RECHTSANWAELTE PART, DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: NOVAGRAAF INTERNATIONAL SA, CH

Ref country code: CH

Ref legal event code: PFUS

Owner name: LG CHEM, LTD., KR

Free format text: FORMER OWNER: LG LIFE SCIENCES LTD., KR

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNG INHABER

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20171102 AND 20171108

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: LG CHEM, LTD., KR

Effective date: 20171208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004046680

Country of ref document: DE

Representative=s name: HOFFMANN EITLE PATENT- UND RECHTSANWAELTE PART, DE

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230523

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230720

Year of fee payment: 20

Ref country code: CH

Payment date: 20230902

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230725

Year of fee payment: 20

Ref country code: DE

Payment date: 20230720

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 602004046680

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20240825

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240825

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240825